Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

MGC Pharmaceuticals' gets access to EU market for ArtemiC to escalate EU exposure and sales

MGC Pharmaceuticals' gets access to EU market for ArtemiC to escalate EU exposure and sales

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, FRA:H5O, ASX:MXC) (LSE:MXC, OTC:MGCLF, FRA:H5O, ASX:MXC) Roby Zomer joins Proactive London's Katie Pilbeam to explain how the approval for sale in the European Union of ArtemiC will impact company.

The firm has been granted a certificate of free sale in Germany which Zomer explains will open up doors to sales in the EU and other international markets.

He says the Free Trade Certificate for ArtemiC Rescue and the ArtemiC product line in Germany, is a significant step forward for MGC Pharma as it opens the EU to the marketing and sale of one of the company's leading products.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK